Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Public ClinicalTrials.gov record NCT05583149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
Study identification
- NCT ID
- NCT05583149
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 28 participants
Conditions and interventions
Conditions
- Refractory Aggressive B-cell Lymphomas
- Refractory B-Cell Non-Hodgkin Lymphoma
- Aggressive B-cell NHL
- Diffuse Large B-cell Lymphoma (DLBCL)
- De Novo or Transformed Indolent B-cell Lymphoma
- DLBCL, Nos Genetic Subtypes
- T Cell/Histiocyte-rich Large B-cell Lymphoma
- EBV-Positive DLBCL, Nos
- Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)
- High-Grade B-Cell Lymphoma, Nos
- C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma
- Grade 3b Follicular Lymphoma
- C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions
- ACALABRUTINIB Drug
- LISOCABTAGENE MARALEUCEL Drug
- Lymphodepleting chemotherapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2023
- Primary completion
- Nov 22, 2024
- Completion
- Feb 28, 2029
- Last update posted
- Jan 28, 2026
2023 – 2029
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02115 | — |
| Beth-Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05583149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05583149 live on ClinicalTrials.gov.